GRAIL, Inc. (GRAL) Research

GRAIL, Inc. is a biotechnology firm dedicated to advancing innovations for detecting cancer at its earliest stages. Among its key offerings is Galleri, a screening test designed for individuals aged 50 and above who show no symptoms of the disease. GRAIL also offers DAC (Diagnostic Aid for Cancer), which assists in expediting the diagnostic process for patients where cancer is clinically suspected. Additionally, the company is actively engaged in the development of minimal residual disease (MRD) tests and various other post-diagnosis solutions. Established in 2015 with its headquarters in Menlo Park, California, GRAIL, Inc. previously operated as a subsidiary of Illumina, Inc.

Market snapshot

Symbol
GRAL
Price
$63.74
Day change
+7.22%
Market cap
$2.7B
P/E ratio
-6.55x
52-week range
29.95-118.84
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 2 months
Analyst price target
$73.43

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Apogee Therapeutics, Inc. (APGE)
  • Celcuity Inc. (CELC)
  • Centessa Pharmaceuticals plc (CNTA)
  • Dyne Therapeutics, Inc. (DYN)
  • IDEAYA Biosciences, Inc. (IDYA)
  • Envista Holdings Corp (NVST)
  • Ultragenyx Pharmaceutical Inc. (RARE)

Recent insider activity

  • Partridge Andrew John — S-Sale (1491 shares) on 2026-06-04
  • Ofman Joshua J. — A-Award (3154 shares) on 2026-06-03
  • Ofman Joshua J. — A-Award (27901 shares) on 2026-06-01
  • Partridge Andrew John — trade (0 shares) on 2026-06-01
  • MIZELL STEVEN — A-Award (396 shares) on 2026-04-15

Open GRAIL, Inc. (GRAL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.